Investing.com - Financial Markets Worldwide

Amplify Weight Loss Drug & Treatment ETF (THNR)

NYSE
Currency in USD
22.87
-0.28(-1.21%)
Closed·
After Hours
22.87-0.04(-0.17%)
·
Day's Range
22.8722.91
52 wk Range
18.5628.19

Key Statistics

Morning Star Rating
-
Risk Rating
-
Bid / Ask
-
Prev. Close
23.15
Price Open
22.91
Volume
1,170
Average Vol. (3m)
2,827
1-Year Change
-18.07%
Day’s Range
22.87-22.91
52-Week Range
18.56-28.19
Market Cap
89.57B
Expense Ratio
0.59%
How do you feel today about THNR?
Vote to see community's results!
or

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Performance

Name
YTD
3M
1Y
3Y
5Y
10Y
Growth of 10009961,021868---
Fund Return-0.43%+2.15%-13.21%---
Rank in Category4342130---
Percentile Rank293276---

Holdings

Eli Lilly and Company

LLY11.40%695.33-2.30%666

Novo Nordisk AS ADR

-8.91%--6,667

Regeneron Pharmaceuticals Inc

REGN7.95%572.38-2.90%551

Amgen Inc

AMGN6.91%288.47-1.79%969

AbbVie Inc

ABBV5.67%207.55-1.45%1,123

Chugai Pharmaceutical Co., Ltd.

45195.64%6,078.0-2.13%5,500

AstraZeneca PLC ADR

-5.59%--2,882

Merck & Company Inc

MRK5.48%85.31-2.36%2,642

Pfizer Inc

PFE5.40%25.14-2.86%8,703

Gilead Sciences Inc

GILD5.40%114.15-0.54%1,928

Amplify Weight Loss Drug & Treatment ETF Company Profile

Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF is an exchange traded fund launched and managed by Amplify Investments LLC. The fund is co-managed by Penserra Capital Management LLC. It invests in public equity markets of global region. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, pharmaceuticals, GLP-1 agonist drugs, drug manufacturers and enablers engaged in outsourced development and manufacturing of GLP-1 agonist drugs sectors. It invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the VettaFi Weight Loss Drug & Treatment Index, by using full replication technique. Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF was formed on May 21, 2024 and is domiciled in the United States.

Industry
-
Sector
-
0
Equity Type
ETF
Market
United States

FAQ

How is the performance of THNR?

As of 26 Aug 2025, THNR is trading at a price of 22.87, with a previous close of 23.15. The stock has fluctuated within a day range of 22.87 to 22.91, while its 52-week range spans from 18.56 to 28.19.

What is the current price of THNR?

The THNR stock price today is 22.87.

Does THNR Pay Dividends? What’s The Current Dividend Yield?

The Amplify Weight Loss Drug & Treatment dividend yield is 0.96%.

What is the ticker symbol for Amplify Weight Loss Drug & Treatment?

The ticker symbol for Amplify Weight Loss Drug & Treatment is THNR.

What is the THNR premarket price?

THNR's last pre-market stock price is 23.15.

What is the THNR after hours price?

THNR's last after hours stock price is 22.87.

What is the P/E ratio of THNR?

The P/E ratio for THNR is 14.45.

What is THNR?

THNR is an ETF issued by Amplify ETFs and is listed and traded on the New York Stock Exchange

From a Technical Analysis Perspective, Is THNR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What is the THNR market cap?

The market cap for THNR is 2.98M.

When is the THNR dividend date?

The next dividend date for THNR is 29 Dec 2024.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.